```
* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:10:43 ON 19 JAN 2008

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'BIOSIS' ENTERED AT 16:11:28 ON 19 JAN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 16:11:28 ON 19 JAN 2008

FILE 'CAPLUS' ENTERED AT 16:11:28 ON 19 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:11:28 ON 19 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 16:11:28 ON 19 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s fluorination (4a) cytosine
L1          29 FLUORINATION (4A) CYTOSINE

=> s l1 and solid support
L2           2 L1 AND SOLID SUPPORT

=> s l2 and 18F
L3           2 L2 AND 18F

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4           2 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 bib abs 1-2

L4   ANSWER 1 OF 2  USPATFULL on STN
AN     2006:143445  USPATFULL
TI     Solid-phase fluorination of uracil and cytosine
IN     Brady, Frank, HAMMERSMITH IMANET LIMITED, CYCLOTRON BUILDING,
       HAMMERSMITH HOSPITAL, DU CANE ROAD, LONDON, UNITED KINGDOM , W12 0NN
       Luthra, Saijnder Kaur, London, UNITED KINGDOM
       Robins, Edward George, London, UNITED KINGDOM
PI     US 2006120958      A1  20060608
AI     US 2003-538904     A1  20031219 (10)
       WO 2003-GB5577         20031219
                              20050614  PCT 371 date
PRAI   GB 2002-29683      20021220
DT     Utility
FS     APPLICATION
LREP   GE HEALTHCARE, INC., IP DEPARTMENT, 101 CARNEGIE CENTER, PRINCETON, NJ,
       08540-6231, US
CLMN   Number of Claims: 12
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention relates to a process for the production of an .sup.
```

18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-I.sup.+-TRACER (I) Y.sup.- wherein the TRACER is of formula (A): or an amine protected derivative thereof, wherein Y.sup.- is an anion, preferably trifluoromethylsulphonate (triflate) anion; and R.sup.1 is either (i) a group CH--NP.sup.1AP.sup.2A in which P.sup.1A and P.sup.2A are each independently hydrogen or a protecting group, or (ii) a carbonyl group; with .sup.18F.sup.- to produce the labelled tracer of formula (II) or an amine protected derivative thereof, wherein R.sup.1 is as defined for the compound of formula (I). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:546427 CAPLUS
DN 141:106482
TI Solid-phase fluorination of uracil and cytosine
IN Brady, Frank; Luthra, Sajinder Kaur; Robins, Edward George
PA Hammersmith Imanet Limited, UK
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056400	A1	20040708	WO 2003-GB5577	20031219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003290297	A1	20040714	AU 2003-290297	20031219
	EP 1572249	A1	20050914	EP 2003-782657	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006510707	T	20060330	JP 2004-561655	20031219
	US 2006120958	A1	20060608	US 2005-538904	20050614
PRAI	GB 2002-29683	A	20021220		
	WO 2003-GB5577	W	20031219		

OS MARPAT 141:106482
GI

Q= 



I



II

AB The invention relates to a process for the production of an 18F -labeled tracer which comprises treatment of a solid support-bound precursor of formula SOLID SUPPORT -LINKER-I+-TRACER.Y- [wherein the TRACER is formula Q or an amine protected derivative thereof; wherein Y- = an anion, preferably trifluoromethylsulfonate (triflate) anion; R1 = either (i) a group CH-NP1AP2A in which P1A and P2A are each independently hydrogen or a protecting group, or (ii) a carbonyl group] with 18F- to produce the 18F-labeled tracer of formula (I) or an amine protected derivative thereof (wherein R1 is as defined above). The 18F -labeled tracers I are useful as radiotracers for positron emission tomog. (PET). Thus, etherification of 4-iodophenol with Wang resin in DMF in the presence of Cs2CO3 at 60° for 3 h gave 4-iodophenyl benzyl ether supported on Wang resin which was treated with Ac2O and H2O2 at 40° overnight to give 4-(diacetoxyiodo)phenyl benzyl ether supported on Wang resin. A suspension of the latter resin in CH2Cl2 was treated dropwise with CF3SO3H at -30 over 15 min, warmed to 0° over 15 min, and stirred at room temperature overnight, cooled to -30°, treated with 5-(dihydroxyboranyl)-1H-pyrimidine-2,4-dione, and stirred at -30° for 1 h and at room temperature overnight to give a resin-supported precursor (II). To a portion of the resin II held in a cartridge was added a solution of kryptofix, K2CO3, and [18F]fluoride and the resulting suspension was heated to 85° for 10 min to give 5-[18F]-fluorouracil.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

```
=> d his

     (FILE 'HOME' ENTERED AT 16:10:43 ON 19 JAN 2008)

     FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:11:28 ON
     19 JAN 2008
L1            29 S FLUORINATION (4A) CYTOSINE
L2             2 S L1 AND SOLID SUPPORT
L3             2 S L2 AND 18F
L4             2 DUP REM L3 (0 DUPLICATES REMOVED)

=> s fluorination and tracers
L5           100 FLUORINATION AND TRACERS

=> s l5 not l4
L6            98 L5 NOT L4

=> s l6 and 18F
L7            69 L6 AND 18F

=> s l7 and solid support
L8            17 L7 AND SOLID SUPPORT

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9            16 DUP REM L8 (1 DUPLICATE REMOVED)

=> s l9 and (cytosine or uracil)
L10            1 L9 AND (CYTOSINE OR URACIL)

=> d l10 bib abs

L10  ANSWER 1 OF 1  USPATFULL on STN
AN     2006:340280  USPATFULL
TI     Radical trap in fluoridation of iodonium salt
IN     Wadsworth, Harry John, Buckinghamshire, UNITED KINGDOM
       Widdowson, David Arthur, London, UNITED KINGDOM
       Wilson, Emmanuelle, London, UNITED KINGDOM
       Carroll, Michael Andrew, Tyne, UNITED KINGDOM
PI     US 2006292060        A1  20061228
AI     US 2004-559879       A1  20041217 (10)
       WO 2004-GB5304           20041217
                                20060830  PCT 371 date
PRAI   GB 2003-29716       20031223
DT     Utility
FS     APPLICATION
LREP   GE HEALTHCARE, INC., IP DEPARTMENT, 101 CARNEGIE CENTER, PRINCETON, NJ,
       08540-6231, US
CLMN   Number of Claims: 17
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Decomposition of iodonium salts by a free radical process has been
       identified as a significant factor in the observed yield variability of
       fluoridation reactions using said iodonium salts. Accordingly, the
       inclusion of a free radical trap in the reaction mixture blocks the
       radical chain decomposition pathway for iodonium salts such that only
       the reaction leading to fluoridation can occur and the yield of aryl
       fluoride becomes high and reproducible. The reaction may also be carried
       out on solid phase. In both the solution and the solid phase the
       preferred method of the present invention is radiofluoridation.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>